See also Imagent®.
June 19, 2003
Alliance Pharmaceutical Corporation and Photogen Technologies, Inc. announced that they have closed the previously announced transaction whereby Photogen has acquired all of the assets of Alliance related to medical imaging, including all manufacturing and marketing rights to Imagent (formerly Imavist). Terms of the transaction were not disclosed.

June 03, 2002
Alliance Pharmaceutical Corp. announced that its ultrasound imaging agent, Imagent (perflexane lipid microspheres), has been approved for marketing by the U.S. Food and Drug Administration. The product will be marketed by Alliance in partnership with Cardinal Health, Inc., a provider of products and services to the healthcare industry, and inChord Communications, Inc., an independent healthcare communications company.

March 01, 2002
'Alliance Pharmaceutical Corp. announced that it has entered into a partnership with Bayer Schering Pharma AG, Germany and Cardinal Health Inc. for the marketing of Imavist (perflexane lipid microspheres), an ultrasound contrast agent. Schering licensed worldwide marketing rights for Imavist from Alliance in September 1997. The companies have agreed to modify this agreement to allow Alliance to increase its participation in the marketing of the product. Under the terms of the modified agreement, Alliance will have exclusive marketing rights to Imavist for cardiology indications in the U.S. for five years, and Schering will receive a royalty on product sales. Schering retains marketing rights for other indications in the U.S. and all indications in the rest of the world, subject to Alliance's option to obtain additional indications and territories. Under certain circumstances, Schering would co-market the product at the end of five years. Concurrently, Alliance has entered into a five-year exclusive agreement with Cardinal Health Inc., a provider of products and services to the health-care industry, to assist in the marketing of Imavist.'

October 08, 2001
'Alliance Pharmaceutical Corp. announced a clinical study to take place at Thomas Jefferson University Hospital, Philadelphia, using Alliance's Imavist (AF0150) contrast agent with ultrasound imaging to improve detection of prostate cancer. The study, which will involve 300 adult men with suspected prostate cancer, is being funded by the U.S. Department of Defense under a competitive grant awarded to Thomas Jefferson University for investigators at Jefferson's Prostate Center. Imavist is being developed jointly by Alliance and Bayer Schering Pharma AG Germany, and is awaiting final approval from the U.S. Food and Drug Administration.'

August 21, 2000
Alliance Pharmaceutical Corp. announced that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the FDA has completed its review of the New Drug Application (NDA) for Imagent (AF0150), and found it to be approvable. Imagent, an ultrasound contrast agent, is being developed jointly by Alliance and Bayer Schering Pharma AG, Germany

Notes:
The manufacturer is pursuing additional radiology indications such as ultrasound imaging of the prostate and liver, and clinical trials are currently being conducted to evaluate Imagent in conjunction with ultrasound imaging for use in the detection of prostate cancer. During the course of its development, the brand name for this product has changed from Imagent to Imavist back to Imagent. Initially reported on by the manufacturer as Imagent and then, between August 2000 and March 2002, as 'Imavist (formerly Imagent).' The manufacturer's 06/03/02 press release announcing FDA approval refers to the product as 'Imagent (formerly Imavist),' and the approval notice and monograph posted at the FDA site refers to the product as Imagent. Jointly developed by Alliance Pharmaceutical Corp and Bayer Schering Pharma AG, (Germany). Source: PR Newswire - 10/10/96, 03/31/98, 10/13/99, 03/13/01, 10/08/01; FDA approvals - 05/31/02; Alliance Pharmaceutical press release - 06/03/02.

Imagent® is an injectable suspension for intravenous administration during a sonogram. This diagnostic contrast agent for enhancement of ultrasound images contains perflexane lipid microspheres. Imagent® US is indicated in the assessment of heart function and perfusion, as well as the detection of tumors and blood flow abnormalities by using gray scale, color Doppler, and harmonic ultrasound imaging techniques.
During the course of its development, the brand name for this product has changed from Imagent to Imavist (between August 2000 and March 2002) back to Imagent. The manufacturer's 06/03/02 press release announcing FDA approval refers to the product as 'Imagent (formerly Imavist),' and the approval notice and monograph posted at the FDA site refers to the product as Imagent.
Jointly developed by Alliance Pharmaceutical Corp and Bayer Schering Pharma AG (Germany). Source: PR Newswire - 10/10/96, 03/31/98, 10/13/99, 03/13/01, 10/08/01; FDA approvals - 05/31/02; Alliance Pharmaceutical press release - 06/03/02.
Currently the production of Imagent® is discontinued.

California-based research and development company. Alliance Pharmaceutical Corporation. The principal activities of the Company is identifying, designing, and developing novel medical products. The Company is engaged in development of scientific discoveries into medical products and licensing these products to multinational pharmaceutical companies in exchange for fixed payments and royalty or profit sharing payments. The Company has developed three innovative products through initial clinical (human) trials. The products are Oxygent™, Liquivent and Imavist™. The Company's strategy is to identify potential new medical products though its own efforts and scientific collaborations with researchers and clinicians in universities and medical centers. In Dec 2000 the company acquired Molecular Biosystems Inc a developer of intravenous ultrasound contrast agent for the heart.

'September 20, 2001 Alliance Pharmaceutical Corp. announced that it has won a favorable Final Judgment from the United States Patent and Trademark Office's Board of Patent Appeals and Interferences regarding claims in U.S. Patent No. 5,558,854, which is owned by Nycomed Imaging, AS. The Final Judgment determined that claims made in the Nycomed patent with respect to 'microbubbles' that contain perfluorohexane filling gas are invalid and are therefore unpatentable.'
June 04, 2010, the company announced in their quartzerly report: 'We no longer have working capital to fund our operations. Because adequate funds have not been available to us in the past, we have already delayed our Oxygent development efforts and have eliminated our other product development programs.'

Ultrasound Contrast Agents: